Patients with diabetes mellitus and atrial fibrillation treated with NOACs: Meta-analysis of 8 outcomes in 58, 634 patients across 4 randomized controlled trials.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | D. McGuire | C. Ruff | Thomas A. Zelniker | Jeong-Gun Park | Anna Plitt
[1] D. Singer,et al. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. , 2017, Journal of the American College of Cardiology.
[2] G. Lip,et al. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants , 2020, Cardiovascular Diabetology.
[3] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[4] E. Braunwald,et al. Atrial Failure as a Clinical Entity: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.
[5] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[6] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.
[7] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[8] D. Giugliano,et al. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans , 1990, Diabetologia.
[9] Kristian Thorlund,et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.
[10] J. Hartung,et al. A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.
[11] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[12] G. Patti,et al. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study‐level meta‐analysis of phase III randomized trials , 2017, Diabetes/metabolism research and reviews.
[13] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. , 2019, Circulation.
[14] J. Healey,et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. , 2014, The Canadian journal of cardiology.
[15] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[16] M. Kaur,et al. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies , 2018, Cardiovascular Diabetology.
[17] B. Sobel,et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. , 1998, Circulation.
[18] A. Eisen,et al. Use of non‐vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus , 2018, Diabetic medicine : a journal of the British Diabetic Association.
[19] J. Shaw,et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. , 2018, Diabetes research and clinical practice.
[20] Jiming Liu,et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.
[21] Christopher P Cannon,et al. Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.
[22] S. Merkel,et al. Diabetes and atrial fibrillation: stratification and prevention of stroke risks , 2014, EPMA Journal.
[23] J. Halperin,et al. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[24] E. Antman,et al. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial , 2018, Circulation.
[25] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[26] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[27] W. Nelson,et al. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. , 2013, The American journal of cardiology.
[28] S. Yusuf,et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. , 2015, International journal of cardiology.
[29] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[30] T. Maddox,et al. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. , 2015, World journal of diabetes.
[31] L. Lund,et al. Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy , 2020, Circulation.
[32] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.
[33] D. Atar,et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. , 2015, European heart journal. Cardiovascular pharmacotherapy.
[34] A. Vinik,et al. Platelet dysfunction in type 2 diabetes. , 2001, Diabetes care.
[35] J. Goldberger,et al. Global rising trends of atrial fibrillation: a major public health concern , 2018, Heart.
[36] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.
[37] D. Lane,et al. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice , 2011, Journal of thrombosis and haemostasis : JTH.
[38] G. Breithardt,et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). , 2015, American heart journal.
[39] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[40] Chih-Cheng Hsu,et al. Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban , 2018, Thrombosis and Haemostasis.
[41] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[42] E. Antman,et al. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. , 2020, International journal of cardiology.